Ghost Tree Capital’s Pacific Biosciences PACB Stock Holding History

Ghost Tree Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-750,000	Closed	-$6.72M	–	88
2016 Q3	$6.72M	Buy	+750,000	New	+$6.27M	1.09%	33
2016 Q2	–	Sell	-700,000	Closed	-$5.95M	–	76
2016 Q1	$5.95M	Sell	700,000 -50,000	-7%	-$492K	3.37%	8
2015 Q4	$9.85M	Buy	+750,000	New	+$6.73M	4.03%	8

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Ghost Tree Capital's PACB Position: Q4 2016 in Review

Ghost Tree Capital sold out of Pacific Biosciences (PACB) in Q4 2016, closing a stake of 750,000 shares — an estimated $6.72M sold.

Ghost Tree Capital first reported a position in PACB in Q4 2015 and held it in 3 quarters. The position peaked at $9.85M in Q4 2015. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

Ghost Tree Capital reported no remaining Pacific Biosciences position as of Q4 2016 after selling out during the quarter.
Ghost Tree Capital sold 750,000 Pacific Biosciences shares in Q4 2016, an estimated $6.72M.
Ghost Tree Capital first reported a position in Pacific Biosciences in Q4 2015 and held it in 3 quarters.
Ghost Tree Capital's Pacific Biosciences position peaked at $9.85M in Q4 2015.
115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.